Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Bridged Bicyclo Compounds, Heterocyclic
  • Carcinoma, Renal Cell
  • Everolimus
  • Kidney Neoplasms
  • Pyrimidines

abstract

  • This study demonstrated that dual PI3K/mTOR inhibition by apitolisib was less effective than was everolimus in mRCC, likely because full blockade of PI3K/mTOR signaling resulted in multiple on-target adverse events. VHL mutation and hypoxia-inducible factor 1α expression may be predictive of an mTOR inhibitor benefit, although prospective validation is required.

publication date

  • May 10, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5569691

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.64.8808

PubMed ID

  • 26951309

Additional Document Info

start page

  • 1660

end page

  • 8

volume

  • 34

number

  • 14